Japanese drugmakers are interested in establishing their main manufacturing sites in Thailand.

Earnings per share were 5.2% higher than that of the same period last year.

The increase occurred mainly due to the worldwide stockpiling of drug ingredients.

This includes the digitization of its core laboratory, handling 60-70% of its annual tests.

The software runs on deep learning and low-cost off-the-shelf hardware.

New technology decreases cell culture time by half, and uses more targeted cell sorting and purification methods.

Local firms will benefit from the government support to improve capacity and supply.

The round was led by SoftBank Vision Fund 2, and the company plans to use the funding to accelerate global expansion.